Abstract
Objective:
To study the associations between androgens, glucose homeostasis, inflammation
and statin treatment in women with polycystic ovary syndrome (PCOS).
Design and methods: Oral glucose tolerance tests, androgens, hs-CRP and interleukin-1 receptor antagonist (IL-1Ra) were analyzed at baseline and after 6months of atorvastatin (20 mg/d) or placebo treatment in 27 women with PCOS.
Results: Testosterone associated with insulin resistance measured with ISIMatsuda independently of BMI, age and SHBG concentrations and the full model, including IL-1Ra, hs-CRP and HDL-C, also showed independency of BMI and waist circumference (p≤.042). Free androgen index (FAI) associated with ISIMatsuda independently of adiposity (p≤.025) but in the full model with waist circumference the association was insignificant. ISIMatsuda decreased with testosterone >1.2nmol/l compared with lower levels at baseline (p=.043) and at six months (p=.003). Accordingly, 30-minute insulin levels were increased with moderately elevated testosterone independently of adiposity (p≤.046). Increased fasting glucose and AUC insulin associated with statin treatment independently of adiposity and the associations attenuated after adjusting for testosterone.
Conclusions: Moderately elevated testosterone concentrations together with obesity-related inflammatory factors modify glucose homeostasis by increasing insulin resistance and early insulin secretion.
Original language | English |
---|---|
Journal | Gynecological Endocrinology |
Volume | 34 |
Issue number | 1 |
Pages (from-to) | 40-44 |
Number of pages | 5 |
ISSN | 0951-3590 |
DOIs | |
Publication status | Published - 2018 |
MoE publication type | A1 Journal article-refereed |
Fields of Science
- 3121 General medicine, internal medicine and other clinical medicine
- 3123 Gynaecology and paediatrics
- Insulin secretion
- insulin sensitivity
- inflammation polycystic ovary syndrome
- adiposity
- androgens
- IL-1 RECEPTOR ANTAGONIST
- GLUCOSE-TOLERANCE
- METABOLIC SYNDROME
- PROSPECTIVE COHORT
- DOUBLE-BLIND
- FOLLOW-UP
- SIMVASTATIN
- SENSITIVITY
- TRIAL
- PCOS